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Quantitative decision models such as multiple criteria decision analysis (MCDA) can be used in benefit-
risk assessment to formalize trade-offs between benefits and risks, providing transparency to the 
assessment process.  There is however no well-established method for propagating uncertainty of 
treatment effects data through such models to provide a sense of the variability of the benefit-risk 
balance.  Here we present a Bayesian statistical method that directly models the outcomes observed in 
randomized placebo-controlled trials and uses this to infer indirect comparisons between competing 
active treatments.  The resulting treatment effects estimates are suitable for use within the MCDA 
setting, and it is possible to derive the distribution of the overall benefit-risk balance through Markov 
Chain Monte Carlo simulation. The method is illustrated using a case study of natalizumab for relapsing-
remitting Multiple Sclerosis. 
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1 Introduction  
1.1 Structured benefit-risk assessment and MCDA 
Benefit-risk assessment involves bringing together evidence on the favourable and unfavourable effects 
of a treatment in order to inform a medical decision, such as the decision by a doctor to prescribe a 
treatment or by a regulator to grant marketing authorisation. 
Within the regulatory context, the importance of transparency in the benefit-risk decision making 
process is increasingly recognised.  Regulators are accountable to the public and should be able to 
explain and defend the basis on which their decisions are made - in other words, it should be possible to 
demonstrate how the evidence has logically led to a certain course of action.  Adopting formal 
structures for benefit-risk assessment can help to provide this level of transparency (Mt-Isa et al., 
2011).  
One method that has attracted attention is multiple criteria decision analysis (MCDA), a formal 
decision-making framework, various formulations of which have been developed and applied in a 
number of fields over the years (Keeney and Raiffa, 1976). The method involves specifying the 
expected consequences of each alternative course of action, and then establishing the utility (or value) 
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of these consequences.  The optimal decision is that which maximizes the value to the decision-maker 
(Ashby and Smith, 2000) and, as the method makes value judgements explicit, it is possible for the 
decision-maker to adopt other stakeholders’ perspectives.  MCDA makes comparisons based on 
multiple criteria – this is achieved by establishing the consequences of each possible course of action in 
relation to each criterion and then calculating the overall value as the sum of the values across all 
criteria, weighted according to their relative importance ().  For this analysis, detailed knowledge of the 
decision-maker’s preferences is required.  For each criterion, a partial value function must be 
established: this ascribes a numerical value to different levels of an outcome variable, indicating how 
importantly the decision maker values a change in that outcome.  Preference weights that specify the 
relative importance of the criteria are also required. A key assumption here is that the partial values of 
different outcomes are independent, a condition known as preference independence. 
Although this method is well-established in many other fields, the use of MCDA in medical settings, 
where the criteria are individual benefits and risks, only emerged in around 2007 (Mussen et al., 2007).  
In the medical context, possible decision-makers include regulators, drug developers, healthcare 
providers, doctors and patients themselves.  Decisions are ultimately made on patients’ behalf and so, 
where value judgements are required as part of a decision model, these are typically elicited from 
patients or their representatives.   
 
1.2 Natalizumab case study 
Natalizumab is a treatment for relapsing-remitting multiple sclerosis, an autoimmune disease 
characterised by periodic symptomatic attacks (relapses), frequently progressing to a state of sustained 
disability due to accumulated neurological damage.  Natalizumab was licensed in the USA in 2004 but 
subsequently withdrawn from the market after post-marketing surveillance revealed a number of fatal 
cases of progressive multifocal leukoencephalopathy (PML) among patients taking the drug.  PML is a 
frequently fatal brain infection caused by the John Cunningham (JC) virus, which is widespread but 
does not pose a threat to immunocompetent individuals.  Natalizumab is believed to allow the JC virus 
to infect the nervous system, leading to PML.  In spite of this risk, the FDA re-introduced the drug in 
2005 due to patient demand.   In the EU, the Committee for Medicinal Products for Human Use first 
approved the drug in 2006.  In 2008 and 2010 it reviewed this decision after further cases of PML were 
observed, deciding to continue approval in both instances. 
The natalizumab case study is part of IMI-PROTECT Work Programme 5 (IMI-PROTECT, 2012).  
This programme aimed to develop methods for use in benefit-risk assessment, including both the 
underpinning modelling and the presentation of the results. The purpose of PROTECT is not to revisit 
any decisions made by regulatory authorities or any other decision maker, but rather to evaluate the 
appropriateness of frameworks and methodologies for benefit-risk assessment. 
The case study seeks to address the question of whether natalizumab should be licensed, based on 
publicly available treatment effects data and using preference information elicited from patients or their 
representatives.  In the initial case study, Nixon et al. (2014) used MCDA as a quantitative tool in 
combination with the PrOACT-URL decision making framework (Hammond et al., 1999).  This paper 
aims to extend this work by considering the impact of data uncertainty using a probabilistic model.  
 
1.3 Sensitivity to uncertainty of treatment effects 
When applying MCDA to a benefit-risk assessment, the alternatives are treatments, and the 
consequences of each alternative are derived from treatment effects data, typically observed in clinical 
trials (or sometimes observational studies or spontaneous reports).  Naturally, any such estimates are 
subject to sampling error.  It is standard practice in medicine for this uncertainty to be reported in study 
results, typically through a 95% confidence interval.  However, there is currently no standard 
probabilistic method for propagating this uncertainty through an MCDA model in order to assess its 
impact on the overall utility of each treatment, as the method uses only point estimates of the treatment 
effects.   Most implementations of MCDA rely on a one-way sensitivity analysis, but this process is 
cumbersome and lacks statistical rigour.  
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A more rounded approach is to use a probabilistic model that uses assumptions about the random 
processes underlying the data in order to gain insight into the expected spread of values.  In benefit-risk 
decision-making, we are not directly concerned with the variability of observed data, or with testing 
hypotheses, but rather with what we can infer about the range of plausible values for the underlying 
population parameters, as it is these that are relevant to the benefit-risk balance.  This leads us to focus 
on Bayesian models, which assign a probability distribution to each input parameter based on the 
likelihood of the data observed in the source studies.  The distribution of the model output (in this case, 
the partial value of each criterion and the overall value associated with each treatment) can then be 
obtained by simulating values from the input distributions and using these in the MCDA model.   
There have been various attempts to use probabilistic models to allow for parameter uncertainty in 
benefit-risk.  Sutton et al. (2005) used Bayesian modelling to derive distributions of the benefit-risk 
balance of warfarin, an anticoagulant.  The benefit-risk balance was expressed within a framework 
known as Net Clinical Benefit (NCB).  The NCB approach is limited, however.  In a mathematical 
sense it can be seen as a special case of MCDA in which only certain kinds of outcomes and/or partial 
value functions are permitted.  We seek to develop a Bayesian model that can be used in a more general 
MCDA setting. 
Hughes et al (2007) used probabilistic methods to allow for uncertainty of treatment effects in 
benefit-risk assessment using a “decision tree” framework that is very similar to MCDA.  However, 
their method relies on evidence from studies directly comparing each treatment, which was not 
available for the natalizumab case study.  Caster et al (2012) extended the approach of Hughes et al 
(2007) by considering the uncertainty of preference data, an extension that could also be applied here.   
Stochastic multi-criteria acceptability analysis (SMAA) is a variation of MCDA, designed for 
situations where preference weights are unknown or only partially known (Lahdelma et al., 1998).  
SMAA ranks alternatives by exploring all possible combinations of weights using MCDA and 
calculating how often each alternative is chosen.  Tervonen et al. (2011) applied this method to benefit-
risk assessment, using the J-SMAA software package (Tervonen, 2012) to carry out a probabilistic 
benefit-risk assessment using Monte Carlo simulations to allow for uncertainty in both clinical 
parameters and preferences.  
SMAA provides a useful method for obtaining results from a multi-criteria decision model in the 
absence of preference data, but it must be recognized that there will usually be a high degree of 
uncertainty associated with the results.  Greater certainty – and therefore better decisions – will 
generally be achieved if preference data are elicited a priori from the relevant stakeholders. 
Furthermore, in its current form J-SMAA only allows uncertainty of treatment effects data to be 
characterized by a small number of closed-form distributions.  This may be adequate for simple 
models, such as when comparisons are made between treatment groups in a single randomized 
controlled trial.  However, within benefit-risk assessment, it is often necessary to pull together evidence 
from many studies using meta-analytical methods to synthesize evidence on a comparable basis. These 
situations require more complex statistical models.  We use a case study to apply a Bayesian approach, 
directly modelling the outcomes observed in placebo-controlled trials for several competing treatments 
for the same indication.  Indirect comparisons between the active treatments are then made, and 
ultimately we derive the distributions of the benefit-risk score for each treatment within a pre-specified 
MCDA model for the case study, details of which are set out below. 
 
1.4 Objectives 
The aims of this paper are: (i) to fit a suitable Bayesian model for the treatment outcome parameters in 
the natalizumab case study, using the original case study data; (ii) to use Markov Chain Monte Carlo 
simulation to generate the distribution of the overall benefit-risk score for each treatment in the case 
study, using the existing MCDA model; and (iii) to consider how the information on the benefit-risk 
distributions, together with appropriate metrics and visualisations, could influence the benefit-risk 
assessment for natalizumab and benefit-risk decision making in general. 
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2 Methods  
2.1 MCDA model and data 
The treatments to be compared, source data and benefit and risk outcomes are the same as those in the 
case study reported by Nixon et al. (2014).   There are three active treatments for relapsing-remitting 
multiple sclerosis: natalizumab, interferon-beta and glatiramer acetate.  The data is drawn principally 
from three clinical trials, one for each active treatment (Polman et al., 2006), (Jacobs et al., 1996), 
(Johnson et al., 1995).  Each trial was of 2 years’ duration.  Not all of the benefits and risks were 
reported in every trial. In cases where no data is available it is assumed either that the number of 
patients experiencing (and not experiencing) an event was the same as in the common placebo group, 
or - for rare events that were not reported - that no events occurred in the relevant trial. 
For PML incidence, no clinical trial data was available.  For natalizumab, post-marketing data from 
an observational study was used (Bloomgren et al., 2012).  As of February 2012, there were 2.1 cases 
of PML per 1000 patients receiving natalizumab.  For all treatments except natalizumab, it was 
assumed that PML incidence was sufficiently low that it could be ignored (i.e. a deterministic value of 
0 was used). 
A disability progression event is defined as a >=1.0 point increase in the Expanded Disability Status 
Scale with a baseline score >=1.0 or a >=1.5 point increase in score with a baseline score of 0, 
confirmed after 6 months.  However, the natalizumab and glatiramer acetate trials used a different 
definition, with disability progression needing to be confirmed after only 3 months. To allow for this, 
the proportion of patients undergoing disability progression was adjusted by a factor of 0.71 in the 
treatment group and 0.79 in the placebo group, based on the results of a trial for fingolimod (another 
multiple sclerosis treatment), which monitored both definitions of the outcome (Kappos et al., 2010).  It 
is acknowledged that the sampling variability of the conversion factor has not been included in the 
statistical model and therefore the variability of the disability progression outcome is likely to have 
been understated for natalizumab and glatiramer acetate; however, we regard this as an issue of data 
quality rather than a fundamental problem with the model. 
Data on hypersensitivity reactions among patients taking glatiramer acetate was taken from the 
drug’s package insert, which is publicly available online (Teva Neuroscience, 2012). 
There were some outcome/treatment combinations for which no data of sufficient quality could be 
found.  In these cases it was assumed either that the proportion of events and sample size observed in 
the relevant study was the same as in the common placebo group, or (for rare events that were not 
reported) that no events occurred in the relevant trial.  These are assumed observations designed to fill 
in gaps in the data and hence allow full testing of the model, rather than deterministic assumptions 
about the underlying event rates which would restrict the model’s functionality. 
A data summary table, showing the source of each item of data, and highlighting where additional 
assumptions have been made, is included in the Supporting Information for this paper.  
The MCDA method requires a pre-specified partial value function for each outcome, which maps 
the observed measure (such as the proportion of patients experiencing an adverse event) to a subjective 
measure of value or utility between 0 (the worst case scenario) and 1 (the best case scenario).  
Similarly, weights must be elicited in order to allow calculation of the overall utility for each treatment 
as a weighted sum of the partial values for all outcomes.  This paper uses the partial value functions 
and weights selected by Nixon et al. (2014) for the natalizumab case study.  The case study aimed to 
assess the benefit-risk balance from a regulatory perspective, with the regulator incorporating the views 
of patients.  Accordingly, linear partial value functions were used, as these implicitly value each patient 
equally.  The best case and worst case scenarios for each outcome were selected to cover the range of 
plausible values: from 0 to 100% for outcomes expressed as proportions, and from 0 to 2 (exceeding 
the upper confidence limits in the source studies), for the 2-year relapse rate.  The final outcome is the 
route of administration, as patients can attach different convenience values to different administration 
methods.  This aspect of treatment is included as a categorical variable, whose outcome is known with 
certainty for each treatment.  The value placed on each route of administration, and the preference 
weights for all outcomes in the value tree, were elicited in decision conferences with patient 
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representatives.  Further information on the case study has been given by Nixon et al. (2014); a 
summary of the key data is provided in Table 1. 
 
<<Table 1 about here>> 
The value functions are expressed in terms of the absolute value of the clinical outcomes, as this is 
the only scale on which the preferences that are fed into MCDA can be unambiguously defined.  
However, direct comparison of the outcomes in the treatment arms of different trials will be vulnerable 
to confounding due to heterogeneities in the baseline rate of events in the trial populations.  In order to 
compare treatments on an absolute scale, a reference population must be chosen. Here we select the 
population of the natalizumab trial, as this can be assumed to be most relevant to the population that 
may benefit from the drug.  
The absolute outcomes in the placebo and natalizumab arms are compared directly: as the trial 
subjects were randomized there should be no baseline heterogeneity.  For the two active comparators, 
direct comparisons are always avoided: instead, the relative effect of each treatment compared to 
placebo is extracted from its own trial, and combine this with the baseline rate in the reference placebo 
population.  This allows for a fair comparison as the reference placebo group is the same for all 
treatments and the relative treatment effect is assumed not to depend on the patient population.  Similar 
methods have been employed for network meta-analysis; see for example Woods et al. (2010).   The 
evidence network is represented in Figure 1, which indicates where direct and indirect comparisons 
have been made. 
<<Figure 1 about here>> 
2.2 Bayesian model 
For a probabilistic implementation of a quantitative benefit-risk assessment, the aim is to express how 
uncertainties in the input parameters affect the uncertainty of the overall result.  This makes Bayesian 
statistics, which permits direct probability statements concerning unknown parameters, a natural fit for 
this purpose. 
In the natalizumab case study there are many parameters.  Ten uncertain clinical outcomes (denoted 
by k=1 to k=10) contribute to the benefit-risk analysis.  Each outcome is observed in as many as six 
different groups of patients (the data is drawn from three clinical trials denoted by i=1,2,3, one for each 
treatment, and each trial has a placebo arm and a treatment arm denoted by j=1,2 respectively).  It is 
assumed that outcomes are independent between trials.  Within each trial it is necessary to model the 
relative treatment effect as this is required for the indirect treatment comparisons. 
The majority of the outcomes to be modeled (PML, seizures, congenital anomalies, reactivation of 
serious viral infections, hypersensitivity reactions, flu-like reactions, elevation of transaminases, 
infusion/injection reactions, disability progression) are binary events at the patient level.  If Xijk is the 
number of patients experiencing event k in arm j of trial i, then Xijk ~ Bin(nijk, πijk) where nijk is the total 
number of patients in the trial arm and πijk is the underlying risk of the event occurring.  Events are 
assumed to occur independently; however an allowance for possible correlations is introduced later as 
part of the sensitivity analysis. 
Let µik = (logit(πi1k)+logit(πi2k))/2, the mean proportion over both arms of the trial, expressed on the 
log-odds scale, and δik = logit(πi1k)-logit(πi2k), the log odds ratio – our relative treatment effect for these 
outcomes. Then logit(πi1k)= µik - δik/2, and logit(πi2k)= µik + δik/2. By use of an appropriate prior, δik can 
be constrained to a range that contains all plausible values for the log odds ratio and allows for some 
correlation between the outcome in the control and treatment arms.  This is consistent with the main 
assumption underlying indirect treatment comparisons, i.e. that the relative treatment effect is relatively 
homogeneous as the baseline event rate varies.  
A strong assumption is made regarding the exchangeability of the δik, which are all assumed to be 
drawn from a common prior across all treatments i and outcomes k. This prior is δik ~ N(d,τ), where τ is 
the precision or inverse variance, with hyperpriors d ~ Unif(-1,1) (noting that this is an average effect 
across all treatments and outcomes, some negative and some positive on the log odds ratio scale) and τ 
~ Gamma(3,1). It is also necessary to specify a prior for µ: this is µik ~ N(0,0.25) where 0.25 is the 
inverse variance. 
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The log-odds transformation is used in order to avoid the possibility of obtaining proportions outside 
the interval (0,1).  This is not the only approach that could be used, however; Bayesian models have 
been developed that operate on other scales such as relative risk and absolute risk difference (Warn et 
al., 2002). 
The binomial likelihood implicitly assumes that all patients have equal exposure to the risk of an 
event.  For disability progression, however, this is not the case: if an individual undergoes a disability 
progression partway through a trial, they are removed from the pool of susceptible individuals, and 
therefore contribute less than 2 years of exposure.  For the sake of simplicity, and due to lack of more 
precise data on the timing of the disability progression events, the model does not allow for this. 
A different model is used for PML.  As this outcome was not observed in any clinical trials, data 
from a post-marketing observational study of natalizumab patients was used along with a different 
statistical model.  Let X ~ Bin(n, π) where n is the number of patients in the post-marketing study, X is 
the number experiencing PML and π is the risk of PML. We use a simple conjugate Bayesian inference 
model for π, with a Beta (1/3,1/3) prior after Kerman (2011).  For placebo and the two remaining active 
treatments it was simply assumed that PML never occurs, which seems a reasonable assumption given 
the nature of PML.  This allows a direct comparison to be made between treatments, so it is not 
necessary to model a relative effect in this case. 
The remaining outcome, relapses (k=10), is expressed in terms of a rate per person-year of exposure 
to treatment.  If Xij,10 is the number of relapses in arm j of trial i (where 1 is the control arm and 2 is the 
placebo arm), then Xij,10 ~ Poisson(nij,10πij,10) where nij,10 is the total patient-years of exposure in the trial 
arm and πij,10 is the underlying event rate. 
Let µi,10 = (log(πi,1,10)+log(πi,2,10))/2, the mean log relapse rate over both arms of the trial, and and 
δi,10 = log(πi,1,10)-log(πi,2,10), the log rate ratio, our relative treatment effect for this outcome. 
Then log(πi,1,10)= µi,10 - δi,10/2, and log(πi,2,10)= µi,10 + δi,10/2.   
The parameters π, δ, µ, the variable X, and the observed data n have slightly different meanings for 
the relapse outcome (k=10 in the BUGS code) than for the binary outcomes (k=1 to 9).  Arguably, δ 
and µ should also be drawn from a different prior.  However, the priors specified above were judged to 
be appropriate for both sets of variables, and so for the sake of parsimony δ and µ have been drawn 
from the same priors for all outcomes in the value tree.  
It is worth noting that the relapse rates corresponding to the raw event and follow-up data (as used 
here) are slightly different from the average rates reported in the published papers (perhaps due to the 
use of covariates in the original analyses of the trials). This results in some minor differences in our 
relapse figures from those reported in Nixon et al. (2014). 
Empirical estimates  ?̂? and µ̂ were calculated using the formulae below.   These estimates were used 
to produce diagnostic plots as an initial check on the suitability of the model.   The formulae for binary 
outcomes are taken from Smith et al. (1995); the formulae for the relapse rate parameters are slightly 
different. 
For the binary outcomes we have:  





























For the relapse rate the formulae used are: 





























For outcomes where both treatment groups in a trial are assumed to experience an event at the same 
rate as the reference placebo group, both the formula for  ?̂?𝑖𝑘 and the priors used in the analysis result 
in an odds ratio that implies an excess of events in whichever trial arm was the larger.  To avoid any 
resulting bias, the sample size in each treatment group is also assumed to match the reference placebo 
group in these instances. 
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The final benefit in the case study is the route of administration for each treatment, which can be 
included in an MCDA model as patients and other stakeholders may have preferences for particular 
routes of administration based on their convenience.  As the route of administration for each treatment 
is known with certainty, and uncertainty of preference data is beyond the scope of this paper, the utility 
associated with this aspect of treatment is modeled deterministically. 
The model for binary outcomes is an adaptation of a model presented by Smith et al. (1995) for 
Bayesian meta-analysis of infections acquired in intensive care units.  Here, the mathematical structure 
of the problem is somewhat different (we have many outcomes, many treatments, and one study per 
treatment rather than one outcome, one treatment, and many studies) but the model is largely 
analogous. We have used the same priors, which we believe are justified on the grounds set out by 
Smith et al. (1995).  The sensitivity to the selection of priors was tested by repeating the analysis using 
various alternative non-informative priors. 
The assumption of exchangeability of δik across treatments (i) for a given outcome (k) seems 
reasonable in the absence of any prior knowledge of each treatment’s clinical effects.  The assumed 
exchangeability across the different clinical outcomes k is perhaps less easy to justify – for any 
particular treatment, there is no reason to suppose a priori that the odds ratio of two seemingly 
unrelated events should be drawn from the same distribution.  To explore the impact of this 
assumption, four alternative model structures for δik were evaluated: (a) a separate random effects 
model for each outcome, exchangeable across treatments; (b) a separate random effects model for each 
treatment, exchangeable across outcomes; (c) no exchangeability across either outcomes or treatments, 
i.e. δik~N(dik,τ); and (d) retaining the assumption of exchangeability across all outcomes and treatments 
but with δik ~ Student-t(d,τ,4), a Student-t distribution with 4 degrees of freedom that is more robust to 
outliers than the Normal distribution, as also suggested by Smith et al. (1995). 
Although the main aim for this case study was to select priors that are not unduly informative, it is 
possible to convey additional information through the use of informative priors if desired.   
The total benefit-risk score is a linear combination of outcome variables, all with negative sign, as 
can be noted by observing that it is the sum of the partial value functions in Table 1. It is therefore to be 
expected that positive correlations between the outcomes will increase the variance of the overall score. 
To explore the impact of this, each outcome’s contribution to the benefit-risk score was estimated in 
the primary analysis; this was then used to calculate the inflated variance of the total score assuming 
various levels of correlation between the outcomes. Further sets of simulations were then run in order 
to compare the treatments’ scores based on the inflated variances and thus assess the potential impact 
of correlations on the overall result.   
 
2.3 Simulations 
Each outcome’s contribution to the benefit-risk score is calculated as the partial value function vk() of 
the relevant outcome measure, which (except in the case of flu-like reactions) is used as observed for 
placebo and natalizumab (a direct comparison) but calibrated on the reference placebo group for beta-
interferon and glatiramer acetate (indirect comparisons).  In other words: the partial value of outcome k 
for placebo and natalizumab is vk [𝜋1,1,𝑘] for placebo and vk [𝜋1,2,𝑘] for natalizumab.  For beta-
interferon (i=2) and glatiramer acetate (i=3), indirect comparisons are necessary: the partial value is vk 
[𝜔−1{𝜔(𝜋1,1,𝑘) × exp(𝛿𝑖𝑘)}] for binary outcomes (where 𝜔 maps probabilities to odds) or vk[𝜋1,1,10 ×
exp⁡(𝛿10,𝑘)] for the relapse rate.  For flu-like reactions, the paucity of data prompted a different 
approach: the reference placebo group is taken from the beta-interferon trial, so some direct 
comparisons become indirect and vice-versa; the calculations are adjusted accordingly (following the 
principle that outcomes observed in different trials are never compared directly).  The overall benefit-
risk score for each treatment is then calculated as the weighted sum of every outcome’s contribution.   
For this illustrative case study the “true” parameter in the reference population is used but, depending 
on the population and the purpose of the benefit-risk assessment, other approaches such as using the 
observed value may be considered appropriate. 
The Markov Chain Monte Carlo simulations were implemented in the WinBUGS software 
package (Lunn et al., 2000). The code is included in the Supporting Information for this paper. 
Comment [EW1]: Move to next 
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In the standard deterministic approach to MCDA, it is straightforward to make decisions 
based on the results of the analysis:  the best alternative to choose is that with the highest overall 
preference-weighted utility or benefit-risk score.  When faced with overlapping distributions of 
uncertain utilities from a probabilistic model, the decision-maker’s task may be less straightforward.  
The decision could be based on the average result, although this would be to ignore the additional 
information on variability provided by a probabilistic analysis.  An alternative decision metric is to 
rank each alternative based on the proportion of simulations in which it had the highest overall utility; 
this is known in SMAA as the rank 1 acceptability index (Tervonen et al., 2011). 
 
3 Results  
The first 5000 simulations were discarded to allow for burn-in, and convergence was checked using the 
diagnostic tools in WinBUGS. 10000 further iterations were then run to obtain samples from the joint 
posterior distribution.  The median overall benefit-risk score for each treatment was checked against 
the results of the corresponding deterministic MCDA model and in each case the relative error was 
below 0.5%. 
<<Figure 2 about here>> 
Figure 2 appears broadly supportive of the assumption that δ and µ are independent. The values all 
lie within the ranges indicated by the priors, suggesting that the choice of prior was reasonable and not 
unduly informative.  The distribution of δ, assumed to be Normal, appears somewhat skewed by two 
outlying values on the right of Figure 2: these are the empirical log odds ratios for outcomes that 
occurred among patients taking a treatment but never occurred in the control arm of the trial 
(hypersensitivity reactions for natalizumab and seizures for beta-interferon). It can also be noted that a 
number of the ?̂?𝑖𝑘 take the precise value zero.  These are the instances where no difference was 
assumed to have been observed between treatment arms (flu-like reactions for natalizumab and 
glatiramer acetate, transaminases elevation for beta-interferon and glatiramer acetate, and 
hypersensitivity reactions for beta-interferon).   
 
<<Figure 3 about here>> 
Figure 3 is a density plot of the posterior distribution of the expected overall benefit-risk score for 
each treatment.  The medians and 95% credibility intervals of the benefit-risk scores for each treatment 
(both in absolute terms and relative to natalizumab) are shown in Table 2, together with the rank 1 
acceptability index, i.e. the probability that each treatment has the highest score.  The total benefit-risk 
scores correspond with those given by Nixon et al (2014) (aside from the slight difference in relapse 
rates noted above) but some figures in that paper are expressed in units corresponding to the utility of 
one disability progression event.  To convert from our measure to theirs (or vice versa), one must 
simply divide (or multiply) by the weight of one disability progression event, i.e. 5.4%. 
 
<<Table 2 about here>> 
<<Table 3 about here>> 
Table 3 illustrates the differential impact of each outcome on the benefit-risk assessment by 
displaying the difference in benefit-risk score between each active treatment and placebo, broken down 
by outcome.  It is a combination of strong preference weighting and differential performance between 
the treatments that results in a large impact for a given outcome.  Most of the impact comes from the 
benefits in the value tree, as the risks are all either infrequently observed or or given a low weight in 
the MCDA model.  It is possible however that the risks could have more impact if different weights 
were used. 
The sensitivity to choice of model structure and hyperpriors for the δik are shown in Table 4, using a 
variety of noninformative priors. Although these variations did have some effect on the posterior 
distributions of the benefit-risk score, it was not enough to have an impact on the overall result 
(natalizumab was still ranked 1
st
 in 100% of the simulations in each case).  Inflating the variance of the 
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benefit-risk score to allow for correlations between outcomes had more effect, but the overall result 
remained robust: with a correlation coefficient of 0.9 between all pairs of outcomes (the strongest 
correlation setting tested) the estimated probability of natalizumab being ranked first was reduced only 
to 96.5%. 
<<Table 4 about here>> 
 
4 Discussion  
MCDA is a powerful decision-making tool but, in its standard deterministic implementation, no 
indication is given of the probability that any observed differences are simply due to sampling error.  
For example, in the case study, interferon beta-1a outperforms glatiramer acetate on the basis of a 
deterministic analysis.  It is only when uncertainty is introduced that one gets a sense of just how 
flimsy this result is.  Similarly, it is only in the light of the probabilistic model – and in particular, the 
rank acceptability index figures - that the robustness of natalizumab’s advantage over the other 
treatments becomes clear.   
The drawback of this approach compared to a deterministic analysis is its relative complexity.  
Fitting statistical models to data on multiple benefits and risks, possibly from many different sources, 
takes considerable resources, and so may not be appropriate for relatively simple benefit-risk 
assessments.  For more finely balanced problems, such as periodic reviews of high-risk products, 
however, probabilistic methods could play an important role.  Bayesian modelling in particular is well 
suited to applications involving hierarchical models or complex evidence networks, or where it is 
necessary to update the analysis from time to time in light of new evidence.  These features are all often 
present in benefit-risk assessment. 
The average benefit-risk score and the rank acceptability index are both reductive measures that 
cannot give the full picture of the distribution of results or the contribution of the individual benefits 
and risks.  There are however a range of visualisations that can be used to communicate this 
information, and the application of visual communication tools to complex benefit-risk problems is an 
active area of study (Mt-Isa et al., 2013).  
Although our focus is on the methodology and we do not seek to comment on the benefit-risk 
balance of natalizumab or its comparators in the real world, it is reassuring to note that our results are 
consistent with previous benefit-risk assessments of the same treatments.  Thompson et al. (2008) 
found natalizumab to have a better benefit-risk profile than beta-interferon, which itself was better than 
placebo. Qizilbash et al. (2008) found that glatiramer acetate and beta-interferon both clearly 
outperformed placebo, but a direct comparison between the two active treatments was more finely 
balanced. We have investigated the robustness of our result to alternative preference weights and found 
that increasing the weight for PML from 53.8% to 93.9% (with the sum of the other weights rescaled to 
6.1% and the ratios between them remaining constant) reduced the probability of natalizumab 
achieving rank 1 from 100% to 95% - still a very strong result. 
The intention for this paper was to develop a model that could be applied as standard to all of the 
outcomes in the value tree, but in the end issues of data quality and asymmetry meant that pragmatic 
alterations had to be made on an outcome-by-outcome and drug-by-drug basis.  For example, the lack 
of consistent endpoint reporting for disability progression meant that a conversion factor had to be 
used, and this introduced additional uncertainty that was not captured in the model.  It was not possible 
to use the same reference placebo group for all outcomes, again due to lack of data.  The pragmatic 
solutions we used to deal with these data problems may not be appropriate in benefit-risk assessments 
for real decision-making purposes, but we consider that we have demonstrated the general utility of our 
approach given appropriate data. The model in this paper incorporated elicited preference information, 
albeit in a deterministic fashion.  There is no reason why the model could not be extended to allow for 
uncertainty of the preference data, and there are many ways this could be achieved.  One possibility is 
to use an SMAA-style algorithm to explore the space of all possible weights.  Another is to directly 
elicit preference distributions.  Alternatively, Caster et al. (2012) proposed a method to take account of 
qualitative preference judgements. Any such model for preference uncertainty could simply be “bolted 
Comment [EW2]: Add a table of 
results? 
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on” to the model presented here, as within the MCDA framework there is no interdependency between 
preferences and outcome measures.  
 
Reproducible Research “code.zip” in the Supporting Information contains the code and data files required to 
generate the results in this paper together with instructions for their use.  Available at: 
http://dx.doi.org/10.1022/bimj.XXXXXXX 
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Figure legends and tables 
 
Figure 1 Evidence network for the case study.  Solid lines represent direct comparisons in studies; dashed 
lines represent indirect comparisons. 
Figure 2 Scattter plot of empirical estimates δ̂ and µ̂ 
Figure 3 Posterior distribution of expected overall benefit-risk score 
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Table 1  Risks, benefits, measures, partial value functions (PVFs) and weights for the natalizumab 
case study 
Endpoint    Measure   PVF   Weight 
Risks:        
PML     % with event in 2 years 1 - proportion  53.8% 
Seizures     % with event in 2 years 1 - proportion  5.4% 
Congenital abnormalities   % with event in 2 years 1 - proportion  5.4% 
Herpes reactivation   % with event in 2 years 1 - proportion  6.4% 
Hypersensitivity reactions  % with event in 2 years 1 - proportion  1.1% 
Flu-like reactions   % with event in 2 years 1 - proportion  1.1% 
Transaminases elevation  % with event in 2 years 1 - proportion  10.7% 
Infusion/injection reactions % with event in 2 years 1 - proportion  2.7% 
Benefits:   
Disability progression   % progressing in 2 years 1 - proportion  5.4% 
Relapses    2-year relapse rate 1 –0.5× rate  7.5% 
Convenience    Route of administration* 1 (daily oral),  0.5% 
       0.7 (monthly infusion), 
       0.5 (weekly intramuscular), 





Table 2    Results: overall benefit-risk (B-R) score.  Medians and (95% credibility intervals).  BI = 
beta-interferon, GA = glatiramer acetate. 
Treatment  B-R score overall  Relative to natalizumab  Probability of rank 1, 2, 3, 4 
Placebo   0.923 (0.919, 0.928)  0.034 (0.029, 0.040) 0.00 0.00 0.12 0.88 
Natalizumab   0.957 (0.954, 0.961) 0.000 (0.000, 0.000) 1.00 0.00 0.00 0.00 
BI  0.931 (0.919, 0.942) 0.026 (0.015, 0.039) 0.00 0.39 0.53 0.08 
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Table 3  The impact of each outcome on the benefit-risk balance of each active treatment relative to 
placebo. 
Endpoint   Contribution to benefit-risk score × 10
3
: active treatment less placebo 
Risks:     Natalizumab Beta-interferon Glatiramer acetate 
PML     -1.14   0.00   0.00 
Seizures      0.15  -0.25  -0.05 
Congenital abnormalities    0.16  -0.04  -0.05 
Herpes reactivation    0.18  -0.08  -0.10 
Hypersensitivity reactions  -0.33  -0.01  -0.02 
Flu-like reactions    0.00  -1.92  -0.02 
Transaminases elevation  -0.91  -0.23  -0.21 
Infusion/injection reactions -1.53  -0.13  -0.43 
Benefits:   
Disability progression    5.59   4.21   1.60 
Relapses     33.6   8.86   14.4 
Convenience    -1.62  -2.70  -5.40 
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Table 4  Median (standard error × 10
3
) benefit-risk score for alternate structures and priors.  In each 
row, the specified prior is changed and the others remain as per the main text.  The Normal parameters 
are mean and precision (inverse variance); the Gamma parameters are shape and rate (inverse scale). 
Prior   Natalizumab Beta-interferon Glatiramer acetate 
Main model: δik exchangeable across treatments and outcomes  
Priors as per main text 0.957 (1.661) 0.931 (5.904) 0.933   (5.959) 
µ ~ N(0,1)   0.957 (1.666) 0.931 (5.544) 0.934   (5.667) 
µ ~ Unif(-100,100)  0.958 (1.629) 0.933 (5.670) 0.934   (6.103) 
d ~ Unif(-0.1,0.1)  0.957 (1.625) 0.931 (5.493) 0.933   (5.648) 
d ~ N(0,1)    0.957 (1.637) 0.931 (5.685) 0.933   (5.966) 
τ ~ Gamma(1,0.1)  0.957 (1.640) 0.931 (5.718) 0.933   (5.852) 
τ ~ Half-Cauchy(25)* 0.958 (1.592) 0.931 (5.733) 0.933   (6.053) 
σ ~ Unif(0,100)**  0.957 (1.614) 0.931 (5.645) 0.933   (6.044)  
(a) δik exchangeable across treatments only 
Priors as per main text 0.957 (1.661) 0.932 (5.904) 0.934   (5.959) 
µ ~ N(0,1)   0.957 (1.684) 0.932 (5.504) 0.934   (5.602) 
µ ~ Unif(-100,100)  0.958 (1.610) 0.932 (5.525) 0.934   (5.914) 
d ~ Unif(-0.1,0.1)  0.957 (1.619) 0.931 (5.583) 0.933   (5.649) 
d ~ N(0,1)    0.958 (1.626) 0.932 (5.719) 0.934   (5.875) 
τ ~ Gamma(1,0.1)  0.957 (1.608) 0.933 (5.422) 0.935   (5.393) 
τ ~ Half-Cauchy(25)* 0.957 (1.638) 0.933 (5.431) 0.934   (5.555) 
σ ~ Unif(0,100)**  0.957 (1.602) 0.932 (5.553) 0.934   (5.592)  
(b) δik exchangeable across outcomes only  
Priors as per main text 0.958 (1.626) 0.930 (6.038) 0.934   (6.267) 
µ ~ N(0,1)   0.957 (1.658) 0.930 (5.926) 0.933   (6.023) 
µ ~ Unif(-100,100)  0.958 (1.641) 0.930 (6.064) 0.934   (6.706) 
d ~ Unif(-0.1,0.1)  0.957 (1.622) 0.931 (5.695) 0.933   (5.735) 
d ~ N(0,1)    0.958 (1.622) 0.930 (5.982) 0.933   (6.399) 
τ ~ Gamma(1,0.1)  0.958 (1.625) 0.930 (5.986) 0.933   (6.349) 
τ ~ Half-Cauchy(25)* 0.958 (1.659) 0.930 (6.023) 0.933   (6.443) 
σ ~ Unif(0,100)**  0.958 (1.670) 0.930 (5.969) 0.933   (6.486) 
(c) δik not exchangeable across outcomes or treatments  
Priors as per main text 0.958 (1.632) 0.931 (5.746) 0.933   (6.279) 
µ ~ N(0,1)   0.957 (1.658) 0.928 (6.079) 0.930   (6.265) 
µ ~ Unif(-100,100)  0.958 (1.638) 0.933 (5.705) 0.935   (6.267) 
d ~ Unif(-0.1,0.1)  0.958 (1.621) 0.931 (5.632) 0.933   (5.620) 
d ~ N(0,1)    0.958 (1.646) 0.931 (5.850) 0.933   (6.854) 
τ ~ Gamma(1,0.1)  0.957 (1.620) 0.931 (5.725) 0.934   (5.988) 
τ ~ Half-Cauchy(25)* 0.957 (1.634) 0.931 (5.697) 0.933   (6.061) 
σ ~ Unif(0,100)**  0.957 (1.662) 0.931 (5.756) 0.934   (6.046)  
(d) δik ~ Student-t(d, τ ,4) (exchangeable across treatments and outcomes) 
Prior as per main text 0.958 (1.638) 0.931 (5.736) 0.933   (6.080) 
µ ~ N(0,1)   0.957 (1.650) 0.931 (5.772) 0.933   (5.576) 
µ ~ Unif(-100,100)  0.958 (1.623) 0.930 (7.457) 0.933   (6.640) 
d ~ Unif(-0.1,0.1)  0.958 (1.614) 0.931 (5.773) 0.933   (5.753) 
d ~ N(0,1)    0.958 (1.631) 0.931 (5.796) 0.933   (6.005) 
τ ~ Gamma(1,0.1)  0.958 (1.617) 0.931 (5.787) 0.933   (5.840) 
τ ~ Half-Cauchy(25)* 0.958 (1.632) 0.931 (5.725) 0.933   (5.927) 
σ ~ Unif(0,100)**  0.958 (1.634) 0.931 (5.813) 0.933   (5.863)  
*Half-Cauchy distribution with scale parameter 25; see Gelman (2006); ** where σ = τ-0.5, 
 
 
